← Back to Search

Constructive Shearwave Interference (CSI) for Breast Cancer

N/A
Waitlist Available
Led By Sarah Jo Stephens, MD
Research Sponsored by Microelastic Ultrasound Systems Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Summary

This trial will test a new ultrasound technology to see if it can measure lymphedema in the upper arms of breast cancer survivors. The goal is to see if it is better than the standard arm tape measurement.

Eligible Conditions
  • Breast Cancer
  • Lymphedema

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference in mean shear wave speed across sites measured between lymphedema and non-lymphedema limbs

Trial Design

1Treatment groups
Experimental Treatment
Group I: CSI ultrasound measurementExperimental Treatment1 Intervention
Participants will have standard volumetric tape measurement across multiple arm locations for lymphedema followed by CSI ultrasound measurements of the same anatomic sites.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Constructive Shearwave Interference (CSI)
2022
N/A
~30

Find a Location

Who is running the clinical trial?

Microelastic Ultrasound Systems IncLead Sponsor
Duke HealthOTHER
5 Previous Clinical Trials
2,776 Total Patients Enrolled
Sarah Jo Stephens, MDPrincipal InvestigatorDuke Health
~7 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top